Regulus Therapeutics (NASDAQ:RGLS) Price Target Increased to $10.00 by Analysts at HC Wainwright

Regulus Therapeutics (NASDAQ:RGLS) had its target price upped by investment analysts at HC Wainwright from $9.00 to $10.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 390.20% from the stock’s current price. HC Wainwright also issued estimates for Regulus Therapeutics’ Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS and Q4 2025 earnings at ($0.20) EPS.

Other equities analysts have also issued reports about the stock. StockNews.com assumed coverage on shares of Regulus Therapeutics in a report on Tuesday, April 16th. They issued a “sell” rating on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Regulus Therapeutics in a research note on Monday, March 18th. Wells Fargo & Company lifted their target price on Regulus Therapeutics from $2.00 to $3.00 and gave the company an “equal weight” rating in a report on Wednesday, March 13th. Canaccord Genuity Group lowered their price target on shares of Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, March 19th. Finally, SVB Leerink assumed coverage on Regulus Therapeutics in a research report on Monday, March 18th. They set an “outperform” rating and a $6.00 target price on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $11.75.

Regulus Therapeutics Trading Down 4.7 %

Shares of Regulus Therapeutics stock opened at $2.04 on Tuesday. The firm’s 50-day moving average price is $2.25 and its 200 day moving average price is $1.91. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.79. The firm has a market capitalization of $133.56 million, a PE ratio of -1.40 and a beta of 1.64.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.14). On average, sell-side analysts predict that Regulus Therapeutics will post -0.59 EPS for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

Large investors have recently bought and sold shares of the company. Opaleye Management Inc. acquired a new position in shares of Regulus Therapeutics during the 1st quarter worth $490,000. RA Capital Management L.P. acquired a new position in Regulus Therapeutics in the 1st quarter valued at $18,000,000. NEA Management Company LLC purchased a new position in Regulus Therapeutics during the first quarter worth about $18,627,000. Vanguard Group Inc. boosted its position in shares of Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after acquiring an additional 453,784 shares during the last quarter. Finally, CVI Holdings LLC acquired a new position in shares of Regulus Therapeutics in the 1st quarter valued at $4,050,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.